OPC-61815 vs Tolvaptan

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Heart Failure

Shared mechanism: Vasopressin V2 receptor · full Heart Failure pipeline

OPC-61815 · Samtasu

Marketed by Otsuka Holdings

Phase 3 in Heart Failuresmall molecule (prodrug)
Partial signal

NCT03772041 · Phase 3 · completed

This randomized, double-blind Phase 3 trial compared intravenous OPC-61815 with oral tolvaptan in heart failure with fluid retention, with a non-inferiority primary endpoint on body-weight change. The published analysis reports that non-inferiority was confirmed (difference -0.31 kg, 95% CI -0.68 to 0.06, against a 0.48 kg margin).

Reported efficacy

Change From Baseline in Body Weight (Baseline, Day 6): Change From Baseline in Body Weight (Baseline, Day 6): OPC-61815 Injection 16 mg -1.67 kg (95% CI -1.93 to -1.41) vs Tolvaptan Tablet 15mg -1.36 kg (95% CI -1.62 to -1.1) (met)

Result source: NCT03772041

Tolvaptan · Samsca

Marketed by Otsuka Holdings

Phase 3 in Heart Failuresmall molecule
Partial signal

NCT00071331 · Phase 3 · completed

This large trial randomly assigned 3,600 people with heart failure to tolvaptan or placebo, with treatment assignment masked. Neither primary outcome favoured tolvaptan: all-cause mortality was 25.9% against 26.3% on placebo (hazard ratio 0.98, 95% CI 0.87 to 1.11, p=0.68), and the combined rate of cardiovascular death or heart-failure hospitalisation was 42.0% against 40.2% (hazard ratio 1.04, 95% CI 0.95 to 1.14, p=0.55). The trial was well built and its answer was that tolvaptan did not change these outcomes.

Reported efficacy

All-cause mortality: tolvaptan 25.9% vs placebo 26.3% (HR 0.98, 95% CI 0.87-1.11, P=.68). Composite of CV death or HF hospitalization: tolvaptan 42.0% vs placebo 40.2% (HR 1.04, 95% CI 0.95-1.14, P=.55). (missed)

Result source: NCT00071331

Results for Heart Failure

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointOPC-61815Tolvaptan
CV death or HF hospitalisation—Not reported—Not posted · NCT00071331
HF hospitalisation—Not reported—Not posted · NCT00071331
CV death—Not reported—Not posted · NCT00071331
KCCQ clinical summary, change—Not reported—Not posted · NCT00071331

CV death or HF hospitalisation

OPC-61815
—Not reported
Tolvaptan
—Not posted · NCT00071331

HF hospitalisation

OPC-61815
—Not reported
Tolvaptan
—Not posted · NCT00071331

CV death

OPC-61815
—Not reported
Tolvaptan
—Not posted · NCT00071331

KCCQ clinical summary, change

OPC-61815
—Not reported
Tolvaptan
—Not posted · NCT00071331
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. OPC-61815: 5 of 5 rows · Tolvaptan: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricOPC-61815Tolvaptan
Weight
absolute change · kg
-1.67 vs -1.36 Tolvaptan kg @ 0.86wk16 mga,b,c,d
NCT03772041 · Phase 3 · monotherapy · Heart Failure · phase 3
-0.8 vs -1.3 placebo kg @ 1.14wk*a,b,c,d
NCT02476409 · Phase 4 · registry result, not featured evidence · converted to kg from -1.8 pounds as posted
3 other source trials
-1.62 vs -0.53 placebo kg15 mg
NCT00234104 · Phase 2 · registry result, not featured evidence
-1.35 vs -0.53 placebo kg30 mg
NCT00234104 · Phase 2 · registry result, not featured evidence
-1.85 vs -0.53 placebo kg45 mg
NCT00234104 · Phase 2 · registry result, not featured evidence
Dropout rate
9.4%16 mge
NCT03772041 · Phase 3 · monotherapy · Heart Failure · phase 3
show 8 more results
—16 mg
NCT03962101 · Phase 3
—8 mg
NCT03962101 · Phase 3
—16 mg
NCT03510663 · Phase 1 · registry result, not featured evidence
—32 mg
NCT03510663 · Phase 1 · registry result, not featured evidence
8.3%16mg
NCT03254108 · Phase na · registry result, not featured evidence
0%8mg
NCT03254108 · Phase na · registry result, not featured evidence
16.7%4mg
NCT03254108 · Phase na · registry result, not featured evidence
0%2mg
NCT03254108 · Phase na · registry result, not featured evidence
0%f
NCT02476409 · Phase 4 · registry result, not featured evidence
show 12 more results
0%
NCT02183792 · Phase 4 · registry result, not featured evidence
0%Tolvaptan High Copeptin
NCT01346072 · Phase 4 · registry result, not featured evidence
0%Tolvaptan Low Copeptin
NCT01346072 · Phase 4 · registry result, not featured evidence
16%
NCT01439009 · Phase 4 · registry result, not featured evidence
23.3%
NCT03255226 · Phase 3 · registry result, not featured evidence
8.5%
NCT01644331 · Phase 3 · registry result, not featured evidence
0%30 mg/day
NCT00544869 · Phase 3 · registry result, not featured evidence
14.3%15 mg/day
NCT00544869 · Phase 3 · registry result, not featured evidence
13.2%15 mg
NCT00462670 · Phase 3 · registry result, not featured evidence
14.7%30 mg
NCT00234104 · Phase 2 · registry result, not featured evidence
3.4%15 mg
NCT00234104 · Phase 2 · registry result, not featured evidence
27.6%45 mg
NCT00234104 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
5.4%16 mge
NCT03772041 · Phase 3 · monotherapy · Heart Failure · phase 3
show 8 more results
—16 mg
NCT03962101 · Phase 3
—8 mg
NCT03962101 · Phase 3
—16 mg
NCT03510663 · Phase 1 · registry result, not featured evidence
—32 mg
NCT03510663 · Phase 1 · registry result, not featured evidence
8.3%16mg
NCT03254108 · Phase na · registry result, not featured evidence
0%8mg
NCT03254108 · Phase na · registry result, not featured evidence
16.7%4mg
NCT03254108 · Phase na · registry result, not featured evidence
0%2mg
NCT03254108 · Phase na · registry result, not featured evidence
—f
NCT02476409 · Phase 4 · registry result, not featured evidence
show 12 more results
—
NCT02183792 · Phase 4 · registry result, not featured evidence
—Tolvaptan High Copeptin
NCT01346072 · Phase 4 · registry result, not featured evidence
—Tolvaptan Low Copeptin
NCT01346072 · Phase 4 · registry result, not featured evidence
—
NCT01439009 · Phase 4 · registry result, not featured evidence
3.3%
NCT03255226 · Phase 3 · registry result, not featured evidence
—
NCT01644331 · Phase 3 · registry result, not featured evidence
0%30 mg/day
NCT00544869 · Phase 3 · registry result, not featured evidence
7.1%15 mg/day
NCT00544869 · Phase 3 · registry result, not featured evidence
9.4%15 mg
NCT00462670 · Phase 3 · registry result, not featured evidence
8.8%30 mg
NCT00234104 · Phase 2 · registry result, not featured evidence
0%15 mg
NCT00234104 · Phase 2 · registry result, not featured evidence
17.2%45 mg
NCT00234104 · Phase 2 · registry result, not featured evidence
Serious AEs
4%16 mge
NCT03772041 · Phase 3 · monotherapy · Heart Failure · phase 3
show 8 more results
0%16 mg
NCT03962101 · Phase 3
5.3%8 mg
NCT03962101 · Phase 3
0%16 mg
NCT03510663 · Phase 1 · registry result, not featured evidence
0%32 mg
NCT03510663 · Phase 1 · registry result, not featured evidence
0%16mg
NCT03254108 · Phase na · registry result, not featured evidence
0%8mg
NCT03254108 · Phase na · registry result, not featured evidence
8.3%4mg
NCT03254108 · Phase na · registry result, not featured evidence
0%2mg
NCT03254108 · Phase na · registry result, not featured evidence
31.6%f
NCT02476409 · Phase 4 · registry result, not featured evidence
show 12 more results
0%
NCT02183792 · Phase 4 · registry result, not featured evidence
0%Tolvaptan High Copeptin
NCT01346072 · Phase 4 · registry result, not featured evidence
0%Tolvaptan Low Copeptin
NCT01346072 · Phase 4 · registry result, not featured evidence
48%
NCT01439009 · Phase 4 · registry result, not featured evidence
1.7%
NCT03255226 · Phase 3 · registry result, not featured evidence
6.2%
NCT01644331 · Phase 3 · registry result, not featured evidence
0%30 mg/day
NCT00544869 · Phase 3 · registry result, not featured evidence
7.7%15 mg/day
NCT00544869 · Phase 3 · registry result, not featured evidence
3.8%15 mg
NCT00462670 · Phase 3 · registry result, not featured evidence
3%30 mg
NCT00234104 · Phase 2 · registry result, not featured evidence
0%15 mg
NCT00234104 · Phase 2 · registry result, not featured evidence
7.1%45 mg
NCT00234104 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
16 mge
dehydration 10.1%
thirst 8.7%
constipation 6%
NCT03772041 · Phase 3 · monotherapy · Heart Failure · phase 3
show 8 more results
16 mg
hypokalaemia 28.6%
constipation 14.3%
delirium 14.3%
NCT03962101 · Phase 3
8 mg
constipation 28.9%
hepatic function abnormal 13.2%
insomnia 10.5%
NCT03962101 · Phase 3
16 mg
nasopharyngitis 2.1% (placebo 0%)
pruritus 2.1% (placebo 0%)
tonsillitis 2.1% (placebo 0%)
NCT03510663 · Phase 1 · registry result, not featured evidence
32 mg
pruritus 8.5% (placebo 0%)
nasopharyngitis 2.1% (placebo 0%)
tonsillitis 2.1% (placebo 0%)
NCT03510663 · Phase 1 · registry result, not featured evidence
16mg
back pain 9.1%
blood creatinine increased 9.1%
blood urea increased 9.1%
NCT03254108 · Phase na · registry result, not featured evidence
8mg
arthralgia 8.3%
blood creatinine increased 8.3%
blood urea increased 8.3%
NCT03254108 · Phase na · registry result, not featured evidence
4mg
vessel puncture site reaction 16.7%
abdominal pain upper 8.3%
acute kidney injury 8.3%
NCT03254108 · Phase na · registry result, not featured evidence
2mg
cardiac failure congestive 7.7%
contusion 7.7%
dizziness 7.7%
NCT03254108 · Phase na · registry result, not featured evidence
f
thirst 20% (placebo 2%)
blood sodium increased 16% (placebo 0%)
constipation 12% (placebo 4%)
NCT01439009 · Phase 4 · registry result, not featured evidence
show 8 more results
thirst 6.7%
anaemia 3.3%
constipation 3.3%
NCT03255226 · Phase 3 · registry result, not featured evidence
worsening heart failure 38% (placebo 46.1%)
acute renal failure 18.6% (placebo 11.7%)
atrial fibrillation 10.1% (placebo 14.8%)
NCT01644331 · Phase 3 · registry result, not featured evidence
30 mg/day
blood alkaline phosphatase increased 50%
blood creatinine increased 50%
blood urea increased 50%
NCT00544869 · Phase 3 · registry result, not featured evidence
15 mg/day
thirst 46.2%
blood creatinine increased 30.8%
blood glucose increased 30.8%
NCT00544869 · Phase 3 · registry result, not featured evidence
15 mg
constipation 17% (placebo 5.3%)
thirst 17% (placebo 1.8%)
blood urea increased 9.4% (placebo 17.5%)
NCT00462670 · Phase 3 · registry result, not featured evidence
30 mg
thirst 27.3% (placebo 10.3%)
constipation 18.2% (placebo 10.3%)
blood uric acid increased 12.1% (placebo 0%)
NCT00234104 · Phase 2 · registry result, not featured evidence
15 mg
blood uric acid increased 21.4% (placebo 0%)
thirst 21.4% (placebo 10.3%)
blood urea increased 10.7% (placebo 3.4%)
NCT00234104 · Phase 2 · registry result, not featured evidence
45 mg
thirst 53.6% (placebo 10.3%)
dehydration 21.4% (placebo 6.9%)
blood pressure decreased 7.1% (placebo 0%)
NCT00234104 · Phase 2 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 4 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 1.14 weeks versus 0.86 weeks.
  5. ePopulation comparability has not been reviewed for 8 of these studies.
  6. fPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

OPC-61815

Lower Limb Edema Improvement 68.9% (n=149) vs 75.7% (n=145) Tolvaptan @ 0.86wk16 mg
responder rate · % of participants
Lower Limb Edema
NCT03772041 · Phase 3 · monotherapy · Heart Failure · phase 3
Pulmonary Congestion Improvement 56.1% (n=149) vs 64.7% (n=145) Tolvaptan @ 0.86wk16 mg
responder rate · % of participants
Pulmonary Congestion
NCT03772041 · Phase 3 · monotherapy · Heart Failure · phase 3
NYHA Improvement 44.9% (n=136) vs 42.5% (n=120) Tolvaptan @ 0.86wk16 mg
responder rate · % of participants
NCT03772041 · Phase 3 · monotherapy · Heart Failure · phase 3

Tolvaptan

Dyspnea VAS 21 vs 15 placebo score @ 0.29wk
absolute change · score
NCT02476409 · Phase 4 · registry result, not featured evidence
Cumulative Urine Output 24 h 2910 vs 3150 Furosemide mL @ 0.142857wk
absolute value · mL
NCT02183792 · Phase 4 · registry result, not featured evidence
Serum Creatinine Change mg/dL -0.08 vs -0.01 Furosemide mg/dL @ 0.14wk
absolute change · mg/dL
Median 24h Change
NCT02183792 · Phase 4 · registry result, not featured evidence
Weight -2.9 kg @ 2wk30 mg/day
absolute change · kg
No placebo or comparator arm
NCT00544869 · Phase 3 · registry result, not featured evidence
show 3 more results
-1.31 kg @ 2wk15 mg/day
NCT00544869 · Phase 3 · registry result, not featured evidence
-1.3 kg
NCT01346072 · Phase 4 · registry result, not featured evidence
-0.4 kg
NCT01346072 · Phase 4 · registry result, not featured evidence
Body Weight -1.99 vs -1.2 placebo kg @ 2.14wk
absolute value · kg
NCT01439009 · Phase 4 · registry result, not featured evidence
Lower Limb Edema Improvement 77.1% (n=35) vs 64% (n=25) placebo @ 2.14wk
event count · % of participants
NCT01439009 · Phase 4 · registry result, not featured evidence · converted to % from 27 participants as posted
NYHA Class Improvement 46.8% (n=47) vs 54.5% (n=44) placebo
event count · % of participants
NCT01439009 · Phase 4 · registry result, not featured evidence · converted to % from 22 participants as posted
Weight Loss 1.7% 22.8% (n=57) @ 0.57wk
responder rate · % of participants
No placebo or comparator arm
NCT03255226 · Phase 3 · registry result, not featured evidence
Urine Volume 53.1% (n=59) @ 0.14wk
absolute change · percentage points
No placebo or comparator arm
NCT03255226 · Phase 3 · registry result, not featured evidence
show 2 more results
47.8% (n=59) @ 0.29wk
NCT03255226 · Phase 3 · registry result, not featured evidence
45.8% (n=59) @ 0.43wk
NCT03255226 · Phase 3 · registry result, not featured evidence
Weight -0.371% (n=57) @ 0.57wk
percent change · % of baseline
No placebo or comparator arm
NCT03255226 · Phase 3 · registry result, not featured evidence
Lower Limb Edema Improvement 68.6% (n=35) @ 0.57wk
responder rate · % of participants
No placebo or comparator arm
NCT03255226 · Phase 3 · registry result, not featured evidence
Pulmonary Congestion Improvement 51.6% (n=31) @ 0.57wk
responder rate · % of participants
No placebo or comparator arm
NCT03255226 · Phase 3 · registry result, not featured evidence

+ 4 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: OPC-61815's landscape · Tolvaptan's landscape